How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition

How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition

Submitted by admin on December 22, 2019 - 12:32am
Source: 
Motley Fool
News Tags: 
Bristol-Myers Squibb
Celgene
M&A
Headline: 
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
snippet: 

Bristol-Myers Squibb (NYSE: BMY) closed on its acquisition of Celgene in November. The big drugmaker announced plans to buy Celgene earlier this year for $74 billion. 

Do Not Allow Advertisers to Use My Personal information